BACKGROUND: The washout rate (WR) of (123)I-metaiodobenzylguanidine (MIBG) is now widely used for assessing the severity of heart failure. Although the WR of MIBG is usually measured at rest, the assessment of WR of MIBG during exercise might have a different clinical relevance. In this study, we measured the WR rate of MIBG during low-grade exercise and studied the clinical importance of this novel index. METHODS: Twenty-four patients with dilated cardiomyopathy (DCM) were enrolled in this study. Planar images were obtained 20 minutes after MIBG injection (first image) and after 270 minutes (second image); the third image was obtained after 15 minutes of low-grade (10 W) bicycle ergometer exercise (300 minutes after MIBG injection). The decay of the specific counts was calculated from the first two images. The estimated third counts were calculated from the resting decay and were compared with the actual third counts. RESULTS: In the receiver operating characteristic (ROC) curve analysis, we set a 10% decrease from the estimated counts as a cut-off value for severe heart failure (New York Heart Association [NYHA] Class IIm or worse). In 15 patients, the actual third count value was within 10% of the estimated count (N-group). In nine patients, the WR during exercise was high, and the actual third count values showed more than a 10% decrease from the estimated count value (H-group). In the H-group, 78% of the patients were in NYHA class IIm or III. In contrast, in the N-group, no patient had NYHA class III, and only 20% of the patients were in class IIm. The brain natriuretic peptide (BNP) level was significantly higher in the H-group than in the N-group (525 ± 263 pg/mL vs 176 ± 144 pg/mL; P < .01). No significant differences were observed in heart/mediastinal (H/M) activity ratio, the regular WR, and left ventricular ejection fraction values between the two groups. CONCLUSIONS: The WR of MIBG during exercise may be an independent prediction variable, with a clinical relevance different from that of the WR at rest. This measurement could be used as a new index for assessing the severity of heart failure.
BACKGROUND: The washout rate (WR) of (123)I-metaiodobenzylguanidine (MIBG) is now widely used for assessing the severity of heart failure. Although the WR of MIBG is usually measured at rest, the assessment of WR of MIBG during exercise might have a different clinical relevance. In this study, we measured the WR rate of MIBG during low-grade exercise and studied the clinical importance of this novel index. METHODS: Twenty-four patients with dilated cardiomyopathy (DCM) were enrolled in this study. Planar images were obtained 20 minutes after MIBG injection (first image) and after 270 minutes (second image); the third image was obtained after 15 minutes of low-grade (10 W) bicycle ergometer exercise (300 minutes after MIBG injection). The decay of the specific counts was calculated from the first two images. The estimated third counts were calculated from the resting decay and were compared with the actual third counts. RESULTS: In the receiver operating characteristic (ROC) curve analysis, we set a 10% decrease from the estimated counts as a cut-off value for severe heart failure (New York Heart Association [NYHA] Class IIm or worse). In 15 patients, the actual third count value was within 10% of the estimated count (N-group). In nine patients, the WR during exercise was high, and the actual third count values showed more than a 10% decrease from the estimated count value (H-group). In the H-group, 78% of the patients were in NYHA class IIm or III. In contrast, in the N-group, no patient had NYHA class III, and only 20% of the patients were in class IIm. The brain natriuretic peptide (BNP) level was significantly higher in the H-group than in the N-group (525 ± 263 pg/mL vs 176 ± 144 pg/mL; P < .01). No significant differences were observed in heart/mediastinal (H/M) activity ratio, the regular WR, and left ventricular ejection fraction values between the two groups. CONCLUSIONS: The WR of MIBG during exercise may be an independent prediction variable, with a clinical relevance different from that of the WR at rest. This measurement could be used as a new index for assessing the severity of heart failure.
Authors: G Eisenhofer; P Friberg; B Rundqvist; A A Quyyumi; G Lambert; D M Kaye; I J Kopin; D S Goldstein; M D Esler Journal: Circulation Date: 1996-05-01 Impact factor: 29.690
Authors: P Merlet; C Benvenuti; D Moyse; F Pouillart; J L Dubois-Randé; A M Duval; D Loisance; A Castaigne; A Syrota Journal: J Nucl Med Date: 1999-06 Impact factor: 10.057
Authors: H Ogita; T Shimonagata; M Fukunami; K Kumagai; T Yamada; Y Asano; A Hirata; M Asai; H Kusuoka; M Hori; N Hoki Journal: Heart Date: 2001-12 Impact factor: 5.994
Authors: A Cohen-Solal; Y Esanu; D Logeart; F Pessione; C Dubois; G Dreyfus; R Gourgon; P Merlet Journal: J Am Coll Cardiol Date: 1999-03 Impact factor: 24.094
Authors: D M Wieland; L E Brown; W L Rogers; K C Worthington; J L Wu; N H Clinthorne; C A Otto; D P Swanson; W H Beierwaltes Journal: J Nucl Med Date: 1981-01 Impact factor: 10.057
Authors: E B Henderson; J K Kahn; J R Corbett; D E Jansen; J J Pippin; P Kulkarni; V Ugolini; M S Akers; C Hansen; L M Buja Journal: Circulation Date: 1988-11 Impact factor: 29.690